Effect of BMS-214662 in blast crisis CML (n = 4) and IM-resistant Ba/F3 cell lines. (A) Total viable cells in blast crisis CML after 6 days culture in the different treatment arms. The addition of BMS-214662 to either IM or dasatinib significantly reduced the number of total viable cells compared with either agent alone (P = .04 for both). (B) Total quiescent CD34⁺ CFSE^max cells present after 6 days of culture. Data are expressed as a percentage of the no drug control, and data are represented as mean plus or minus SEM. (C) Forty-eight–hour proliferation assays for Ba/F3 cell lines with different BCR-ABL kinase mutations after treatment with BMS-214662. Data are the mean of 3 experiments with 5 replicates in each experiment.